Current Research Studies

Cancer – H-42691: A Trial of Atovaquone (MEPRON) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults

Condition or Therapy:

Acute Myeloid Leukemia (AML)

Category:

Cancer and Blood Disorders
Study Number: H-42691

What is the goal of this study?

The goals of this study are:

To collect data on the patient and family experience of giving daily atovaquone to patients during their first month of AML treatment.
To collect information about whether atovaquone kills cancer cells from children with AML, using research laboratory studies.
To learn more about how atovaquone kills cancer cells from children with AML.
To help determine the best way to include atovaquone in pediatric AML treatments in the future.

Who can join the study?

This study may be a good fit for children and young adults who:

Are between 1 month and 21 years old
Are newly diagnosed with acute myelogenous leukemia

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Todd Cooper
Research Center: Center for Clinical and Translational Research

Looking for a Researcher?

Name: First Name Last Name
Area of Focus: Research Center:

©1995–2020 Seattle Children’s Hospital

4800 Sand Point Way NE,

Seattle,

WA

98105

206-987-2000

866-987-2000 (toll-free)

206-987-0391 (TTY)

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.